HOWL Werewolf Therapeutics
- 6.160
- -0.230-3.60%
Werewolf Therapeutics News
Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Werewolf Therapeutics Analyst Ratings
Buy Rating Affirmed for Werewolf Therapeutics With Anticipated Surge on WTX-124 Phase 1 Data Release
Buy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform Developments
Analysts' Top Healthcare Picks: Werewolf Therapeutics (HOWL), AbbVie (ABBV)
Promising Preliminary Phase 1 Data and Strong INDUKINE Platform Basis for Buy Rating on Werewolf Therapeutics: A Leerink Partners Analysis
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Werewolf Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Oric Pharmaceuticals (ORIC) and Acadia Healthcare (ACHC)
Promising Initial Safety Updates and Potential Upside Drive Buy Rating for Werewolf Therapeutics' Stock
Analysts Are Bullish on These Healthcare Stocks: Werewolf Therapeutics (HOWL), Ascendis Pharma (ASND)
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Werewolf Therapeutics Analyst Ratings
Promising Potential of Werewolf Therapeutics' WTX-124: A Buy Rating Recommendation and Comparative Analysis With IL-2 Therapy
Werewolf Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Werewolf Therapeutics (HOWL)
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Werewolf Therapeutics (HOWL)
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Werewolf Therapeutics Analyst Ratings
Analysis
Price Target
No Data
